Advertisement

Topics

Search Results for "Breast Pap Test Trial"

00:02 EDT 24th May 2017 | BioPortfolio

Matching Channels

Sniff test

Schilling test

Spirometry Test

The gold standard in lung testing In the same way that blood pressure measurements provide a simple yet effective screening method for cardiovascular disease, spirometry tests can help to unmask t...

Breast Lumps

OncoDEEP

At OncoDNA, our philosophy is to provide the most suitable test in terms of rapidity and cost. That’s why we follow a 3 tier approach to find tumour mutations which can respond to new cancer t...

Matching News

FALCON Breast Cancer Trial: Who's Naive Here?

In the FALCON trial, fulvestrant improved PFS in ER+ metastatic breast cancer patients who were endocrine-therapy naive, but the trial failed to answer key clinical questions, says Dr Lidia Schapira. ...

Blood test offers improved breast cancer detection new tool to reduce use of breast biopsy

(Provista Diagnostics) Clinical Breast Cancer study demonstrates Videssa Breast can inform better next steps after abnormal mammogram results & potentially reduce biopsies up to 67%.

Blood test offers improved breast cancer detection tool to reduce use of breast biopsy

(Provista Diagnostics) A Clinical Breast Cancer study demonstrates Videssa Breast can inform better next steps after abnormal mammogram results and potentially reduce biopsies up to 67 percent.

Oncotype DX test can help guide treatment decisions and enable personalized care before breast cancer surgery

New data presented at the 2016 San Antonio Breast Cancer Symposium (SABCS) demonstrate that analyzing tumor biology with the Oncotype DX test can identify patients unlikely to benefit from chemotherap...

Merrimack halts breast cancer treatment trial

Merrimack Pharmaceuticals has stopped a phase 2 trial of its breast cancer treatment after an analysis suggested the drug would unlikely show benefit over the comparator treatments.

Global Cancer Diagnostic Market with Focus on Lung and Breast Cancer 20162020 Prices from USD $800

Scope of the ReportThe report entitled Global Cancer Diagnostic Market with Focus on Lung and Breast Cancer 20162020, provides analysis of the global cancer diagnostics market and the US cancer diagno...

5 Questions on Breast Cancer

In black patients with breast cancer, what type of treatment attenuated aggressive recurrent rates? What percentage of women with early-stage invasive breast cancer report at least one severe/very sev...

BriaCell files CMC amendment and preps for breast cancer vaccine trial

BriaCell Therapeutics Corp. has submitted a chemistry, manufacturing and control (CMC) amendment to the US FDA before its planned stem-cell based vaccine trial for late stage breast cancer. 

Matching PubMed Articles

Prognostic Factors For Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial.

Prognostic factors of ipsilateral breast tumor recurrence (IBTR) may change over time following breast-conserving therapy.

The BIG 2.04 MRC/EORTC SUPREMO Trial: pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk breast cancer.

SUPREMO is a phase 3 randomised trial evaluating radiotherapy post-mastectomy for intermediate-risk breast cancer. 1688 patients were enrolled from 16 countries between 2006 and 2013. We report the re...

No breast cancer subgroup can be spared postoperative radiotherapy after breast-conserving surgery. Fifteen-year results from the Swedish Breast Cancer Group randomised trial, SweBCG 91 RT.

Breast-conserving surgery (BCS) followed by radiotherapy (RT) is an established treatment for women with T1-2N0 breast cancers. Since subgroups of patients have low ipsilateral breast tumour recurrenc...

Trial sponsorship and self-reported conflicts of interest in breast cancer radiation therapy: An analysis of prospective clinical trials.

We aim to assess any association between study and self-reported conflict of interest (COI) or trial sponsorship in breast cancer radiation clinical trials.

Trial 1 Versus Trial 2 of the Test of Memory Malingering: Evaluating Accuracy Without a "Gold Standard".

This study examines the accuracy of the Test of Memory Malingering (TOMM), a frequently administered measure for evaluating effort during neurocognitive testing. In the last few years, several authors...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement